Nasdaq (Nasdaq:NDAQ) announced that trading of DBV Technologies (Nasdaq:DBVT), a clinical-stage specialty biopharmaceutical company, commenced on The Nasdaq Stock Market on October 22, 2014.
Headquartered in Bagneux, France, DBV Technologies is a biopharmaceutical company focused on changing the field of immunotherapy by developing a novel technology platform called Viaskin®. The company's therapeutic approach is based on epicutaneous immunotherapy, or EPIT®, a proprietary method of delivering biologically active compounds to the immune system through intact skin using Viaskin. DBV Technologies is focusing on severe food allergies, including milk and peanut, for which there are currently no effective treatments. DBV Technologies was incorporated in 2002.
"As allergies become increasingly prevalent as a major health issue, DBV Technologies continues to evolve and innovate in this field," said Adam Kostyál, Senior Vice President, Listing Services, Nasdaq. "We are proud to have DBV Technologies listed on The Nasdaq Stock Market."
By listing with Nasdaq, DBV Technologies joins many of the world's largest and most revolutionary companies. Nasdaq has been the exchange of choice to 93 percent of healthcare companies listed in the U.S. markets.